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Measurement of the concentration of iron in the skin, if 
correlated with total body iron stores, may enable better 
informed decisions on when to initiate, change or stop 
therapy in hereditary heamochromatosis. Naïve haemo- 
chromatosis patients with iron overload and with 
C282Y and/or H63D HFE mutations were evaluated 
at the following time-points: disease diagnosis, end of 
the therapy programme, and 6 months after the end of 
therapy. The distribution and concentration of iron in 
the skin were assessed by quantitative nuclear micro-
scopy methods, in parallel with serum and plasma iron 
concentration. Iron content in the liver was determined 
by nuclear magnetic resonance. Iron accumulated in the 
epidermis; its concentration increased from outer to in-
ner layers, being maximal in the basal layer (7.33 ± 0.98 
µmol/g). At all 3 time-points, most of the iron was asso-
ciated with the extracellular space. During the phleboto-
my programme the iron content of the skin and the liver 
decreased by a factor of 2. These data suggest that mea-
surements of iron concentration in the epidermis, which 
is a readily accessible tissue, reflect iron overload in the 
liver. Key words: skin; iron distribution; haemochromato-
sis; proton microscopy.
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Hereditary haemochromatosis (HH) is a disease caused 
by increased intestinal absorption of iron, resulting in its 
accumulation in multiple organs, such as the liver, heart, 
pancreas (1, 2) and skin (3), causing fibrosis and affecting 
their function. It is generally agreed that the C282Y and 
H63D mutations of the HFE gene are responsible for 
hereditary haemochromatosis (1), and both mutations 
are presently considered in HH screening. The C282Y 
mutation modifies the structure of the HFE protein, ab-
rogating its association with the transferrin receptor and 
causing iron storage overload (4). The physiological role 
of the H63D mutation is less studied, although in vitro 
studies have shown that the affinity between the trans-
ferrin receptors and Fe-transferrin is reduced (4). Large 
population studies have shown that both the compound 
heterozygous and homozygous H63D genotypes have 
much lower penetrance than the C282Y homozygous 
genotype (1, 2). In the haemochromatosis phenotype, 
hyper-ferritinaemia, transferrin saturation (1,5) and 
increased hepatic iron concentration (6) are associated 
with H63D homo- or hetero-zygosity as observed with 
C282Y homozygotes or C282/H63D.
The diagnosis of haemochromatosis is based on ge-
netic testing and indirect serological markers (7), which 
may not accurately reflect tissue overload of iron, as 
they can be influenced by other clinical conditions (8). 
Although non-invasive magnetic resonance imaging 
(MRI) of the liver is often sufficient to assess the iron 
overload status, some cases require confirmation by 
invasive hepatic biopsy (9, 10). 
However, invasive techniques are not appropriate for 
serial observations and follow-up during periodic phle-
botomies (7), which limits iron availability to tissues by 
removing iron from the circulation. Thus, new indicators 
and strategies to provide direct or indirect information 
on organ iron overload are needed. Because of its acces-
sibility, skin is an organ of choice in this context. Helpful 
cross-sectional and longitudinal information can be ob-
tained readily regarding the amount of iron deposition 
during a given time period and the clearance of iron from 
parenchymatous tissues by therapy intervention. Detailed 
studies on distribution and quantitation of iron in the skin 
in patients with HH have however not yet been carried 
out. There are few reports on iron distribution in normal 
human skin (11, 12), in patients with thalassaemia (13), 
and in animal models (14, 15).
The main objective of the present study was therefore 
to assess the appropriateness of skin as an indicator of 
organ iron deposition, and of therapy efficacy, by mea-
suring iron concentration in the skin, in combination 
with conventional blood tests, plasma and serum iron 
concentrations, and the concentration of iron in the liver 
assessed by MRI. 
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MATERIALS AND METHoDS
Patients
A total of 28 patients, over 18 years of age, with elevated iron 
levels (18 men and 10 women; mean age ± SD 50 ± 14 years) 
diagnosed with HH for the first time were enrolled in the study 
(demographic, biological and resonance data from patients at 
diagnosis are shown in Table SI1). All patients were diagnosed 
on the basis of the usual clinical and biochemical data and 
the most frequent mutations on the HFE gene. Recommended 
biochemical blood tests for screening of haemochromatosis 
were performed, including serum ferritin (Ferr), transferrin 
saturation (TS) and total iron-binding capacity (TIBC). Blood 
cells, platelets counts, glycaemia and liver function evaluation 
were also performed. Liver iron content (LIC) was measured 
by quantitative MRI. The patients were either symptomatic or 
asymptomatic. They underwent phlebotomy therapy weekly (as 
tolerated) along with therapy for other relevant co-morbidities, 
such as cirrhosis, hepatocarcinoma, hepatitis C virus infection, 
diabetes mellitus, porphyria cutanea tarda, and steatohepatitis 
(Table SI1). The number of phlebotomies, volume of blood 
withdrawn per course, treatment duration, and total amount of 
iron removed during the therapy programme, varied according 
to the patient’s condition. During treatment, patients underwent 
dietary adjustment. The clinical results were evaluated by fol-
lowing the evolution of blood iron indicators, with the aim of 
reaching ferritin levels of 50–100 ng/ml.
Study design
Patients were assessed at 3 time-points: Phase 1: at disease 
diagnosis, prior to phlebotomy therapy; Phase 2: at the end of 
the phlebotomy therapy programme; and Phase 3: 6 months 
after stopping the therapy programme. 
Biochemical blood tests, LIC and determinations of iron 
content in the skin were performed in all patients before starting 
the therapy programme, at the end of the therapy programme, 
and during follow-up. Measurements performed during the 
pre-therapeutic and subsequent phases were synchronized. 
Informed consent was obtained for all subjects, in accordance 
with the Declaration of Helsinki, and the study was approved 
by the local ethics committee.
Sampling and methods
Blood samples were collected by venipuncture. Serum and 
plasma were separated by centrifugation (2,500 rpm, 10 min) 
and stored at –80ºC. 
Skin was obtained by a 3-mm diameter punch biopsy from 
the lumbar-sacral region. Biopsies were quench-frozen in li-
quid nitrogen and stored at –80ºC until processing. only one 
biopsy at a time was taken from each patient. Sections 14-µm 
thick were cut from the frozen biopsy in a cryostat at –25ºC 
(Cryotome 620E, Thermo Shandon, Cheshire, UK), dried and 
mounted in specific frames, as described elsewhere (16).
serum iron concentration (s-Fe) was determined by the stan-
dard colorimetric method (together with TIBC determination), 
and plasma iron concentration (p-Fe) was determined by total 
reflection X-ray fluorescence (17).
Distribution and concentration profiles of iron in transverse 
sections of cryopreserved skin samples were compiled by 
nuclear microscopy using a combination of 3 techniques (16): 
(i) particle-induced X-ray emission (PIXE), (ii) Rutherford 
backscattering spectroscopy (RBS), and (iii) scanning trans-
mission ion microscopy (STIM). This method has the unique 
capability of providing real-time morphological images and 
maps of multiple elements above sodium in the periodic table 
and, simultaneously, to quantify them down to the level of 
parts per million.
Nuclear microscopy was performed in the “Ion Beam Labo-
ratory” of the IST/ITN. A focused 2.0 MeV proton beam with 
a spot size of 2–3 µm was used to scan across a selected area 
of interest of the skin cryosection. Data from the 3 techniques 
were obtained simultaneously. Images of the sample density 
were obtained by STIM and used to identify skin morphology. 
The concentration of iron was determined by PIXE with high 
quantitative accuracy and with a sensitivity of approximately 
1 µg/g in biological material, such as tissue sections and cells. 
The concentration of matrix constituents was obtained by RBS. 
The distribution images of Fe were superimposed on the density 
images. Consequently, Fe concentrations can be associated 
directly with morphological details of the skin. Concentration 
profiles were obtained by analysing a sequential number of 
points (corresponding approximately to the focused beam area) 
along a transept of the scanned skin section. Skin cryo-sections 
were analysed in vacuum, and iron concentrations in the skin 
were expressed in µmol/g on a dry weight basis. 
System characteristics, data acquisition, and the method for 
calculation of concentration have been described previously 
(16).
MRI was performed at the Radiology Service of Hospital 
de santa Maria, with a 0.5-T gyroscan T5-nT system (philips 
Medical System, Best, The Netherlands). The MRI results 
were analysed by an experienced radiologist. Briefly, the MRI 
technique consists of 3 gradient echo sequences (T1, proton 
density, and long-echo time sequence T2) following the protocol 
established by gandon et al. (18). This protocol is based on a 
T2-weighted gradient-recalled-echo, gRE sequence, which 
was found to be the most sensitive, allowing the detection of 
clinically relevant liver iron overload greater than 60 µmol/g, 
with 89% sensitivity and 80% specificity, and was validated 
with biochemical measures of hepatic iron concentration (18). 
The repetition time (TR), echo time (TE) and pulse angle used 
in the gradient echo sequences to obtain the T1, proton density 
and T2 images were: T1: 120 ms, 14 ms, 90º; proton density: 120 
ms, 14 ms, 20º; and T2: 120 ms, 28 ms, 20º, respectively. To as-
sess possible hepatic lesions the whole liver was first inspected 
using T1-weighted spin-echo (T1-SE) sequence. Afterwards, 
6 magnetic resonance sections were taken for each sequence 
and one of the sections chosen to evaluate the signal intensity 
(SI), in order to avoid global variations in SI between images. 
The SI in the hepatic parenchyma was measured in 3 regions 
of interest > 1 cm2 and in the paraspinal muscles in 2 regions 
of interest. After calculating the mean of the measurements, 
the liver-to-muscle SI ratio was calculated for each sequence 
and these values inputted to the program for calculation of LIC 
(available at the University of Rennes Website; www.radio.univ-
rennes1.fr). This calculation was performed for all patients. 
Statistical analysis
statistical analysis of the data included a χ2 test to compare 
categorical variables, and non-parametric Mann–Whitney test 
to compare continuous variables. Differences between treatment 
phases were calculated with non-parametric Wilcoxon pair test. 
Correlations between iron concentration in the skin and blood 
test values were examined by Spearman’s correlation coefficient 
using rank and linear regression analyses. A linear mixed-
effects regression model was used to fit the phase-dependent 
iron content variations in the liver and skin, taking sex, age, 
co-morbidities and genotype into consideration as confounders. 
The model took into account that, for each patient, the mea-1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-1601
Acta Derm Venereol 94
16 T. Pinheiro et al.
surements at 3 different time-points are associated. To comply 
with normality requirements, iron concentration variables were 
log-transformed. 
Values of p < 0.05 (two-tailed) were considered statistically 
significant. Calculations were performed using SPSS (version 
17.0) and R (version 2.7.0) software packages.
RESULTS
Iron distribution in the skin
Fig. 1 shows images of transversal cryo-sections of skin 
obtained by nuclear microscopy techniques with spatial 
resolution of approximately 2 µm. By measuring the 
energy loss of each ion impinging at each position in the 
scanned area, an image can be formed that represents the 
mass distribution within the tissue. Mass density images 
of selected skin regions evidenced morphological details 
(Fig. 1a) that can easily be associated with histological 
features. By measuring the emitted X-rays from the iron 
atoms present in the tissue, an image of the distribution 
of the element is also produced (Fig. 1B). superposition 
of the distribution with the mass density map allows 
determination of the exact location of the element. Fig. 
1C shows that the iron concentration increases from the 
stratum corneum (where iron levels were lowest) to the 
inner layers, peaking at the basal layer and decreasing 
in the papillary dermis. For comparison, data extracted 
from healthy skin is also shown in Fig. 1C. a similar 
iron distribution profile is observed, which agrees with 
that reported in previous studies (16, 19). 
Skin iron changes during treatment and follow-up
The iron concentrations during therapy were exami-
ned in the major strata, i.e. the stratum corneum (SC), 
stratum spinosum (SP), basal layer (BL), and papillary 
dermis (PD). Iron concentrations were also measured 
in total epidermis (EPI) by combining the data for 
all epidermal strata, and in superficial skin (ssK) by 
combining the data for the epidermis and papillary 
dermis. Results obtained for patients with HH are sum-
marized in Table SII1), which also reports data from 
healthy skin. 
At Phase 1, when compared to control values, iron 
levels were significantly augmented in all skin regions 
with the exception of SC (Table I). After stopping the 
phlebotomy programme (Phase 2) skin iron content 
dropped drastically and continued to decrease until 
Phase 3. However, control levels were reached only at 
Phase 2 in SP and at Phase 3 in BL. At Phase 3, high 
iron levels were still measured in PD, EPI and SSK.
During therapy and 6 months after the end of the phle-
botomies, the iron content measured in SC, SP and BL 
strata decreased to control values, but the iron levels in 
SSK and its major components, EPI and PD, remained 
significantly augmented. By contrast, no change in sC 
iron levels is observed during the 3 evaluation phases 
when compared with controls.
Iron distribution at the cellular level
Using the high-resolution mass density images, and 
taking advantage of the small beam size, epidermal 
cells can be visualized and the iron profiles of cells 
obtained. Extracellular and intracellular iron content 
can therefore be measured. Due to the complexity 
of the analysis, a sub-set of 6 patients with HH was 
randomly selected. The analysis was performed only 
in cryosections where basal keratinocytes could be in-
dividualized. In addition, cryosections were inspected 
Fig. 1. (A) Mass density, and (B) iron distribution in a transverse section of haemochromatosis skin (50 × 90 µm2). The mass distribution is grey-coded: 
the highest mass/iron content is coded white. The coded images are plotted as a 2-dimensional contour map. The dotted line in B indicates the upper limit 
of the stratum corneum. sp: stratum spinosum; pd: papillary dermis; arrows: basal layer. (C) Iron profiles, from the outermost layer (stratum corneum) to 
papillary dermis, as indicated by the vertical dashed line in (B) in skin sections of one patient (Phase 1) and one control skin sample (CTR).
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under the light microscope (bright-field and/or dark-
field reflection microscopy) prior to analysis, in order 
to assess cell overlap and cell sizes. In frozen-hydrated 
tissues, cells above the basal membrane ranged from 
10 µm to 15 µm in diameter, corresponding approx-
imately to the section thickness (14 µm). The tissue 
contracted slightly after the freeze-drying procedure, 
as observed in Fig. 2. Fig. 2 shows a mass density 
image of keratinocytes lying above the basal cells and 
the corresponding iron map. Iron deposits within the 
extracellular and cell membrane compartments can be 
observed. In phlebotomy naïve patients, extracellular 
iron concentration significantly exceeded the intracel-
lular content (10.3 ± 1.3 µmol/g vs. 4.8 ± 0.9 µmol/g; 
p < 0.001). At Phases 2 and 3 the iron concentrations 
inside and outside the cells diminished remarkably. 
However, the extracellular rate of iron clearance was 
lower than that of intracellular clearance. At Phase 2, 
the extracellular iron concentration was 2.2-fold higher 
than that inside the cells (2.8 ± 2.2 µmol/g vs. 1.3 ± 1.0 
µmol/g; p = 0.02) and, at Phase 3, the ratio increased to 
3.2 (2.7 ± 2.0 µmol/g vs. 0.9 ± 0.5 µmol/g; p < 0.001).
Modifiers of iron concentrations in the skin
Iron concentrations in HH skin (whether considering 
major components or individual strata) were not de-
pendent on sex or gender. Also, co-morbidities did not 
influence iron concentration in the skin. The genotype 
was significantly associated with iron concentration in 
the skin only at Phase 12.
Relationship between concentration of iron in the skin, 
blood indicators, and concentration of iron in the liver
At Phase 1, the concentration of iron in all regions of 
HH skin was correlated with blood Ts, Ferr and p-Fe 
(p < 0.05). s-Fe did not correlate with EpI and ssK 
iron content. A strong correlation was found between 
LIC and SP, BL, EPI and SSK (p < 0.001). The decrease 
in LIC was comparable with that in skin, showing a 
progressive and significant decline up to 6 months af-
ter stopping the therapy programme. By contrast, data 
might suggest a trend towards an increase in Ferr, Ts, 
sFe and pFe iron levels at phase 3 (Table SII1).
Despite different LIC and SSK values, a 2.2-fold iron 
content decrease was observed in going from Phase 1 
to Phase 2, but this decrease was limited to 1.2-fold 
between Phase 2 and Phase 3 in both organs (values 
are shown in Tables I and SII1)3.
overall, it can be deduced that the iron concentration 
in BL, EPI and SSK was correlated with LIC throughout 
the treatment and follow-up. Iron content in the skin was 
correlated with Ferr and Ts only in non-treated patients. 
Significance of time-dependent iron content changes 
studied by regression analysis
The overall iron contents of the skin and the liver were 
significantly correlated (Fig. 3). The changes in iron 
concentration as a function of time for all patients in 
Table I. Mean iron concentrations (µmol/g dry weight) in control 
skin (17, 20) and in patients with hereditary haemochromatosis, 
measured at diagnosis, end of the phlebotomy programme, and 
6 months after the end of the programme (Phase 1, 2 and 3, 
respectively)
Control Phase 1 Phase 2 Phase 3
Stratum corneum 1.25 ± 0.32 1.54 ± 0.32 0.83 ± 0.20 1.50 ± 0.75
Stratum spinosum 0.49 ± 0.06 1.44 ± 0.32*,a,c 0.59 ± 0.08 0.55 ± 0.08
Basal layer 1.77 ± 0.46 7.33 ± 0.98*,a,c 2.71 ± 0.36* 2.08 ± 0.36
Papillary dermis 0.98 ± 0.30 3.00 ± 0.50*,a,c 1.78 ± 0.44* 1.89 ± 0.60*
Total epidermis 0.98 ± 0.30 4.10 ± 0.56*,a,c 1.58 ± 0.22*,b 1.18 ± 0.20*
superficial skin 0.98 ± 0.26 3.81 ± 0.42*,a,c 1.64 ± 0.20* 1.35 ± 0.22*
*significantly different from controls; asignificant difference between 
Phase 1 and Phase 2; bsignificant difference between phase 2 and phase 3; 
csignificant difference between phase 1 and phase 3.
Fig. 2. (A) High-resolution image of lower epidermis region showing a few cells likely to be keratinocytes 
in the basal layer (arrows) above papillary dermis (pd). (B) Corresponding iron map (32 × 38 µm2). 
The cell contours and basal layer limit (dotted lines) taken from mass density image were added to 
the iron map to facilitate interpretation. The highest mass density and iron content are coded black.
2Patients with single H63D mutation had 
significantly higher iron concentrations in BL, 
EPI and SSK (n = 5; BL = 7.7 ± 1.6 µmol/g; 
EPI = 5.3 ± 0.9 µmol/g; SSK = 4.7 ± 0.7 µmol/g) 
than C282Y homozygous patients (n = 14; 
BL = 5.8 ± 1.4 µmol/g; EPI = 3.9 ± 1.1 µmol/g; 
SSK = 3.3 ± 0.8 µmol/g) or C282Y heterozygous 
(n = 9; BL = 4.6 ± 0.8 µmol/g; EPI = 2.9 ± 0.7 
µmol/g; SSK = 2.8 ± 0.6 µmol/g). However, the 
decrease in iron concentration during Phase 2 and 
the follow-up does not depend on the genotype.
3 Similar rate of decrease in the iron content was 
observed with individual stratum, ranging from 
1.7 in PD to 2.4 in BL between Phases 1 and 2 
and from 1.4 in BL to 0.9 in SC and PD between 
Phases 2 and 3. The iron content decrease in BL, 
EPI, SSK and liver from Phase 1 to Phase 2 and 
Phase 3 was also correlated with the amount of 
iron removed during therapy (p < 0.05).
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SP, BL, EPI and SSK, from Phase 1 to Phase 2 and to 
phase 3 were highly significant (p < 0.001)4. While the 
amount of iron removed is marginally correlated with 
the decrease in concentration of iron in the skin in going 
from Phase 1 to Phase 2 (p = 0.07), a high statistical 
significance is obtained with phase 3, which reflects 
the therapeutic effect5.
DISCUSSIoN
The present work demonstrates that, in patients with 
primary HH, the iron content of epidermis, reflects iron 
overload in the liver. Although LIC is now rarely deter-
mined through invasive liver biopsies, but rather by MRI 
measurements, it is worth noting that iron assessment 
by MRI may be influenced by tissue condition and re-
laxation properties of the tissue iron (20). Although iron 
deposition occurs in dermis around adnexal structures, 
the nuclear microscopy imaging demonstrates that the 
BL is the preferential site of uniform iron deposition 
in the skin, and is therefore adequate for quantitation 
purposes. This method has the unique capability to pro-
vide real-time morphological images, maps of multiple 
elements and, simultaneously, to quantify them down to 
the level of parts per million. Iron determination in skin 
sections can be achieved rapidly, in approximately 2 h; 
thus this method can be used routinely. It is therefore 
a powerful research tool for dermatology (16, 19), al-
lowing precise follow-up of the clearance of iron from 
tissues during phlebotomy therapy.
The BL is the most metabolically active region of the 
skin, where cell proliferation and differentiation occur, 
iron being indispensable for these processes. Even in 
control skin, the iron content in the BL is higher than 
that in other parts of the skin. Interestingly, nuclear 
imaging demonstrates that iron is found preferentially 
in the extracellular space or bound to cell membrane. 
In addition, data obtained with this method suggest that 
the iron concentration in BL, EPI and SSK is correlated 
with the circulating ferritin content. 
The apparent discrepancy between our results in 
HH epidermis and those described in the experimental 
mouse model by Adams et al. (15) is probably related 
to the skin isolation procedure, which may wash away 
most of the extracellular iron.
The consequence of the excess iron distribution in the 
skin of patients with HH must be discussed in the light of 
cell iron metabolism. In all cells, iron uptake and storage 
are tightly regulated to guarantee sufficient iron for es-
sential cellular processes and to prevent the production 
of damaging free radicals. In hepatocyte membrane, it 
is hypothesized that a homozygous C282Y mutation of 
the HFE gene prohibits the assembly of the transferrin-
receptor 1 (TFR1) with the HFE protein, thereby com-
promising the cellular influx of transferrin-bound iron 
from the endosomal compartment to the cytosol (21, 22). 
The iron-binding capacity of transferrin in the plasma 
of patients with HH is often exceeded. In this study, 14 
out of 28 patients had 70% or more transferrin satura-
tion. Non-transferrin-bound iron is present as low-mo-
lecular-mass iron complexes of citrate and acetate (23, 
24). These low-molecular-mass complexes can initiate 
free radical damage as they supply iron ions in a form 
capable of accelerating free radical reactions and lipid 
peroxidation (25). In this regard, iron sensitizes cultu-
red human skin fibroblasts to the ultraviolet a (Uva) 
radiation when cells are treated with low molecular mass 
complexes or exposed to high ferritin and holotransfer-
rin concentrations with evidence of increased membrane 
lipid peroxidation and cytotoxicity (26) and activation 
of MAP kinases (27). The present study, showing that 
the extracellular space is the major site of excess iron 
deposition in the skin of patients with HH (Figs 1B and 
2), might provide evidence about the lack of notable 
UVA-induced skin sensitization.
genotype may contribute to iron overload with va-
riable penetrance and phenotypic expression may be 
Fig. 3. Relationship between iron concentration in the skin and the liver in 
patients with hereditary haemochromatosis. Solid lines: regression for total 
epidermis (EpI); and superficial skin (ssK). Dashed lines: corresponding 
95% confidence intervals (EpI: skin iron = 44+0.97*LIC, r = 0.448, 
p = 0.0001; ssK: skin iron = 66+0.66*LIC, r = 0.39, p = 0.0009).
4The changes in SP, BL, EPI and SSK iron content with time were associated 
with changes in LIC (p < 0.05), the EpI variations being the most significant 
(p = 0.008). The decrease in Ferr content was correlated with the iron content 
decrease in BL (p = 0.001), SP (p = 0.003) and EPI (p = 0.002) showing a 
steeper mean trend in the decrease in iron content in going from Phase 1 to 
phase 2. However, incorporating Ts, pFe and sFe values into the regression 
models used with skin failed to be significant in going from phase 1 to phases 
2 and 3. This means that the levels of these indicators do not contribute to 
the mean trend of change in iron concentration in the skin.
5It is of note that the genotype did not influence changes in skin iron as a 
function of time. By contrast, in the case of LIC, the average slope of the 
mean rate of decrease in iron content was significantly modified in the 
C282Y genotype p = 0.021). In liver, the iron changes during therapy were 
also correlated with the Ferr (p = 0.05) and TS (p = 0.003) levels in blood.
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influenced by cofactors (8, 28–30) and other additive 
individual factors (1, 5, 28). It is therefore reasonable to 
observe a lack of significance in the correlation between 
iron blood indicators and body stores, such as skin and 
liver over a long time-period. This raises the possibility 
that, in some cases, there is a differential cellular iron 
handling, which results in variable accumulation of iron 
(5, 6, 8, 15, 28–30).
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